Literature DB >> 30215672

Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.

.   

Abstract

Recognizing the importance of timely guidance regarding the rapidly evolving field of hepatitis C management, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) developed a web-based process for the expeditious formulation and dissemination of evidence-based recommendations. Launched in 2014, the hepatitis C virus (HCV) guidance website undergoes periodic updates as necessitated by availability of new therapeutic agents and/or research data. A major update was released electronically in September 2017, prompted primarily by approval of new direct-acting antiviral agents and expansion of the guidance's scope. This update summarizes the latest release of the HCV guidance and focuses on new or amended recommendations since the previous September 2015 print publication. The recommendations herein were developed by volunteer hepatology and infectious disease experts representing AASLD and IDSA and have been peer reviewed and approved by each society's governing board.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30215672      PMCID: PMC7190892          DOI: 10.1093/cid/ciy585

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  100 in total

1.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

2.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

Authors:  Tarik Asselah; Kris V Kowdley; Neddie Zadeikis; Stanley Wang; Tarek Hassanein; Yves Horsmans; Massimo Colombo; Filipe Calinas; Humberto Aguilar; Victor de Ledinghen; Parvez S Mantry; Christophe Hezode; Rui Tato Marinho; Kosh Agarwal; Frederik Nevens; Magdy Elkhashab; Jens Kort; Ran Liu; Teresa I Ng; Preethi Krishnan; Chih-Wei Lin; Federico J Mensa
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-22       Impact factor: 11.382

3.  Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C.

Authors:  Zobair M Younossi; Maria Stepanova; Linda Henry; Edward Gane; Ira M Jacobson; Eric Lawitz; David Nelson; Lynn Gerber; Fatema Nader; Sharon Hunt
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-06       Impact factor: 11.382

4.  Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.

Authors:  Zobair M Younossi; Yushan Jiang; Nathaniel J Smith; Maria Stepanova; Rachel Beckerman
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

5.  Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  David L Wyles; Peter J Ruane; Mark S Sulkowski; Douglas Dieterich; Anne Luetkemeyer; Timothy R Morgan; Kenneth E Sherman; Robin Dretler; Dawn Fishbein; Joseph C Gathe; Sarah Henn; Federico Hinestrosa; Charles Huynh; Cheryl McDonald; Anthony Mills; Edgar Turner Overton; Moti Ramgopal; Bruce Rashbaum; Graham Ray; Anthony Scarsella; Joseph Yozviak; Fiona McPhee; Zhaohui Liu; Eric Hughes; Philip D Yin; Stephanie Noviello; Peter Ackerman
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

6.  Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

Authors:  Zachary D Goodman; Hala R Makhlouf; Lea Liu; William Balistreri; Regino P Gonzalez-Peralta; Barbara Haber; Maureen M Jonas; Parvathi Mohan; Jean P Molleston; Karen F Murray; Michael R Narkewicz; Philip Rosenthal; Lesley J Smith; Patricia R Robuck; Kathleen B Schwarz
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.

Authors:  David Wyles; Norbert Bräu; Shyam Kottilil; Eric S Daar; Peter Ruane; Kimberly Workowski; Anne Luetkemeyer; Oluwatoyin Adeyemi; Arthur Y Kim; Brian Doehle; K C Huang; Erik Mogalian; Anu Osinusi; John McNally; Diana M Brainard; John G McHutchison; Susanna Naggie; Mark Sulkowski
Journal:  Clin Infect Dis       Date:  2017-07-01       Impact factor: 9.079

9.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885.

Authors:  Kelly A Wong; Angela Worth; Ross Martin; Evguenia Svarovskaia; Diana M Brainard; Eric Lawitz; Michael D Miller; Hongmei Mo
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

View more
  154 in total

1.  Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study.

Authors:  Kali Zhou; Norah A Terrault
Journal:  Clin Gastroenterol Hepatol       Date:  2019-06-04       Impact factor: 11.382

2.  Reply to MacDonald et al.

Authors:  Eshan U Patel; Shruti H Mehta; Denali Boon; Thomas C Quinn; David L Thomas; Aaron A R Tobian
Journal:  Clin Infect Dis       Date:  2020-01-16       Impact factor: 9.079

3.  Plasma Golgi protein 73 levels predict prognosis of HCV-related hepatic fibrosis.

Authors:  Lingdi Liu; Zaid Al-Dhamin; Xiwei Yuan; Luyao Cui; Yang Yang; Wen Zhao; Ying Zhang; Na Fu; Yuemin Nan
Journal:  Histol Histopathol       Date:  2020-10-14       Impact factor: 2.303

4.  Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation.

Authors:  Ashly E Jordan; David C Perlman; Charles M Cleland; Katarzyna Wyka; Bruce R Schackman; Denis Nash
Journal:  J Clin Virol       Date:  2020-01-27       Impact factor: 3.168

Review 5.  Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States.

Authors:  Mary Clare Masters; Karen M Krueger; Janna L Williams; Lindsay Morrison; Susan E Cohn
Journal:  Expert Rev Clin Pharmacol       Date:  2019-12       Impact factor: 5.045

6.  Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region.

Authors:  Necati Örmeci; Murat Taner Gülşen; Orhan Sezgin; Sevda Aghayeva; Mehmet Demir; Iftihar Köksal; Rahmet Güner; Elife Erarslan; Özgün Ömer Asiller; Ayhan Balkan; Serkan Yaraş; Aysun Çalışkan Kartal
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

7.  Association of human immunodeficiency virus and hepatitis C virus infection with long-term outcomes post-ST segment elevation myocardial infarction in a disadvantaged urban community.

Authors:  Sanyog G Shitole; Mark H Kuniholm; David B Hanna; Thomas Boucher; Angel Y Peng; Cecilia Berardi; Tina Shah; Anna E Bortnick; Panagiota Christia; James Scheuer; Jorge R Kizer
Journal:  Atherosclerosis       Date:  2020-08-27       Impact factor: 5.162

8.  Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy.

Authors:  Jessica Su; Joseph K Lim
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-11

9.  Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.

Authors:  Luis Margusino-Framiñán; Purificación Cid-Silva; Sandra Rotea-Salvo; Álvaro Mena-de-Cea; Francisco Suárez-López; Pilar Vázquez-Rodríguez; Manuel Delgado-Blanco; Ana Isabel Sanclaudio-Luhia; Isabel Martín-Herranz; Ángeles Castro-Iglesias
Journal:  Eur J Hosp Pharm       Date:  2020-02-07

10.  Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Authors:  Bülent Değertekin; Mehmet Demir; Ulus S Akarca; Haluk Tarık Kani; Enver Üçbilek; Emre Yıldırım; Fatih Güzelbulut; Ayhan Balkan; Sezgin Vatansever; Nilay Danış; Melek Demircan; Aliye Soylu; Serkan Yaras; Aysun Kartal; Ayşe Kefeli; Feyza Gündüz; Kendal Yalçın; Elife Erarslan; Murat Aladağ; Murat Harputluoğlu; Ayşegül Özakyol; Tuncer Temel; Mesut Akarsu; Hale Sümer; Mete Akın; Bülent Albayrak; İlker Sen; Hüseyin Alkım; Ahmet Uyanıkoğlu; Kader Irak; Sinem Öztaşkın; Çağrı Burak Uğurlu; Şevkican Güneş; Selim Gürel; Kenan Nuriyev; İsmail İnci; Sabite Kaçar; Dinç Dinçer; Levent Doğanay; Hüseyin Savaş Göktürk; Ali Mert; Arif Mansur Coşar; Hakan Dursun; Roni Atalay; Sabiye Akbulut; Yasemin Balkan; Hayrettin Koklu; Halis Şimşek; Osman Özdoğan; Mehmet Çoban
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.